Drug Trial Radar · NCT06992687
A Study to Evaluate the Safety and Efficacy of HB0052 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: May 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
30
Planned (sponsor's estimate)
Start
Sep 1, 2024
Primary completion
Sep 30, 2025
Study completion Nov 30, 2025
Sponsor
- Lead sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Peking University Cancer Hospital & Institute; Zhejiang Cancer Hospital; Shandong Cancer Hospital and Institute; Hunan Cancer Hospital; The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School; The Second Affiliated Hospital of Harbin Medical University; Huazhong University of Science and Technology
- First posted
- May 28, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety and tolerability of HB0052 in patients with advanced solid tumors
Conditions
- Solid Tumors
Interventions
HB0052 InjectionDrug
An antibody- drug conjugate (ADC) that targets CD73 with SN38 as the payload
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerabilityTime frame: Up to 12 Months
- MTDTime frame: Up to 24 Months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University Cancer Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.